Biota Holdings Limited is engaged in the drug discovery and clinical development of anti-infectives, suitable for human use and commercialization. The Company licensed zanamivir, which is a neuraminidase inhibitor (influenza antiviral), to GlaxoSmithKline (GSK) and marketed as Relenza. The Company’s research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. The Company has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, the Company and Daiichi Sankyo co-own a range of second generation influenza antivirals, of which the lead product lnavir, is approved for marketing in Japan.